RA0363

antibody from Oursmab

Targeting: IL22 IL-21, IL-22, IL-D110, IL-TIF, ILTIF, MGC79382, MGC79384, TIFa, TIFIL-23, zcyto18

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0363

Provider

Oursmab

Product name

Fezakinumab (Biosimilar Reference Antibody) (IL22)

Antibody type

Monoclonal

Description

Fezakinumab (development code ILV-094) is an investigational, fully human monoclonal IgG1 antibody developed for the treatment of inflammatory and autoimmune diseases, particularly rheumatoid arthritis (RA) and psoriasis. It functions as a selective interleukin-22 (IL-22) inhibitor. By binding with high affinity to IL-22 in the circulation, fezakinumab prevents the cytokine from interacting with its receptor complex, IL-22R1 and IL-10R2, which is expressed on epithelial cells and certain immune cells in tissues such as the skin and joints. This blockade inhibits the downstream pro-inflammatory and tissue-remodeling signals driven by IL-22, aiming to reduce inflammation, hyperproliferation, and tissue damage characteristic of these diseases.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.